Orchid Pharma Sets July 23, 2026, as Record Date for Share Exchange Post-Amalgamation
Orchid Pharma's Board approved the amalgamation with Dhanuka Laboratories, effective July 10, 2026. The record date for share issuance is July 23, 2026. The share exchange ratio is 161:5. Authorized capital increased to ₹164.51 crore.
The amalgamation and share exchange are significant corporate actions that will alter the company's capital structure and shareholder base, impacting future operations and financial reporting. The record date is a crucial step towards integration.
The announcement details the successful completion of an amalgamation and the fixing of a record date for share issuance, indicating a positive step in the company's corporate restructuring.
Orchid Pharma Limited announced that its Board of Directors, in a meeting concluded on July 10, 2026, approved key aspects of its amalgamation with Dhanuka Laboratories Limited (DLL).
The Scheme of Amalgamation has become effective from July 10, 2026, with the appointed date being April 1, 2024. As a result of the amalgamation, DLL stands dissolved without being wound up.
The authorized share capital of Orchid Pharma Limited has been increased to ₹164.51 crore (16,45,10,000 equity shares of ₹10 each). This increase is due to the transfer and amalgamation of DLL's authorized capital.
Furthermore, a record date has been fixed for Thursday, July 23, 2026, to determine the shareholders of the Amalgamating Company (DLL) who will receive shares in the Amalgamated Company (Orchid Pharma Limited).
The approved share exchange ratio is 161 fully paid-up equity shares of Orchid Pharma Limited (face value ₹10 each) for every 5 fully paid-up equity shares of Dhanuka Laboratories Limited (face value ₹100 each).
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.